Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
About this item
Full title
Author / Creator
KEYNOTE-045 Investigators , Bellmunt, Joaquim , de Wit, Ronald , Vaughn, David J , Fradet, Yves , Lee, Jae-Lyun , Fong, Lawrence , Vogelzang, Nicholas J , Climent, Miguel A , Petrylak, Daniel P , Choueiri, Toni K , Necchi, Andrea , Gerritsen, Winald , Gurney, Howard , Quinn, David I , Culine, Stéphane , Sternberg, Cora N , Mai, Yabing , Poehlein, Christian H , Perini, Rodolfo F and Bajorin, Dean F
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
In a randomized trial involving 542 patients with relapsed urothelial cancer, treatment with pembrolizumab resulted in overall survival of more than 10 months, as compared with 7 months with chemotherapy.
Urothelial cancer is highly lethal in the metastatic state.
1
Platinum-based combination chemotherapy remains the standard first-line tr...
Alternative Titles
Full title
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Authors, Artists and Contributors
Author / Creator
Bellmunt, Joaquim
de Wit, Ronald
Vaughn, David J
Fradet, Yves
Lee, Jae-Lyun
Fong, Lawrence
Vogelzang, Nicholas J
Climent, Miguel A
Petrylak, Daniel P
Choueiri, Toni K
Necchi, Andrea
Gerritsen, Winald
Gurney, Howard
Quinn, David I
Culine, Stéphane
Sternberg, Cora N
Mai, Yabing
Poehlein, Christian H
Perini, Rodolfo F
Bajorin, Dean F
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5635424
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5635424
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1613683
